Skip to main content
Signal8
Launch Terminal

CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

CRISPR Therapeutics AG logo

CRISPR Therapeutics AG

NASDAQ:CRSPHealthcare
-5.23%$51.42
AH$51.14-0.54%vs close
Mkt Cap$4.97B
Float78.42M
O/S96.69M
Vol
$ Vol
RVOL
Inst Own78.7%
SI21.0%
Earnings
Dilution
CRISPR Therapeutics AG logoNASDAQ:CRSP$51.42-5.23%
Phase Distribution
16 lead-sponsored trials·6 active·3 completed
Phase 17
Phase 1/28
Not applicable1
(5 more as collaborator)
Status Overview
Not yet recruiting2
Recruiting6
Completed3
Stopped5

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 1/2
    Terminated

    A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

    CTX110

    B-cell Malignancy, Non-Hodgkin Lymphoma +2

    Enrollment
    93
    Start
    Jul 2019
    Primary Completion
    Oct 2024
    Completion
    Oct 2024
    NCT04035434
  • Phase 1/2
    Recruiting

    A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

    CTX112

    B-cell Lymphoma, Non-Hodgkin Lymphoma +6

    Enrollment
    120
    Start
    Mar 2023
    Primary Completion
    Jan 2030est.
    Completion
    Feb 2030est.
    NCT05643742
  • Phase 1/2
    Completed

    A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

    CTX131

    Clear Cell Renal Cell Carcinoma, Cervical Carcinoma +3

    Enrollment
    19
    Start
    Mar 2023
    Primary Completion
    Sep 2025
    Completion
    Sep 2025
    NCT05795595
  • Phase 1/2
    Completed

    A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

    CTX131

    T Cell Lymphoma, B Cell Lymphoma +1

    Enrollment
    12
    Start
    Aug 2024
    Primary Completion
    Mar 2026
    Completion
    Mar 2026
    NCT06492304
  • Phase 1/2
    Recruiting

    Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

    CTX112

    Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia +2

    Enrollment
    60
    Start
    Jul 2026
    Primary Completion
    Dec 2033est.
    Completion
    Dec 2033est.
    NCT07549698
  • Phase 1/2
    Recruiting

    A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension

    CTX340, Placebo

    Hypertension

    Enrollment
    69
    Start
    Aug 2026est.
    Primary Completion
    Jul 2028est.
    Completion
    Jul 2029est.
    NCT07758634
  • Phase 1/2
    Not yet recruiting

    A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease

    CTX112

    Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica +3

    Enrollment
    220
    Start
    Nov 2026est.
    Primary Completion
    Dec 2029est.
    Completion
    Dec 2029est.
    NCT07804004
  • Phase 1/2
    Not yet recruiting

    A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)

    CTX460

    Alpha-1 Antitrypsin Deficiency (AATD)

    Enrollment
    68
    Start
    Oct 2026est.
    Primary Completion
    Jun 2030est.
    Completion
    Jun 2030est.
    NCT07850076
  • Phase 1
    Terminated

    A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

    CTX120

    Multiple Myeloma

    Enrollment
    26
    Start
    Jan 2020
    Primary Completion
    Jan 2024
    Completion
    Jan 2024
    NCT04244656
  • Phase 1
    Terminated

    A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

    CTX130

    Renal Cell Carcinoma

    Enrollment
    19
    Start
    Jun 2020
    Primary Completion
    Oct 2024
    Completion
    Oct 2024
    NCT04438083
  • Phase 1
    Terminated

    A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

    CTX130

    T Cell Lymphoma

    Enrollment
    49
    Start
    Jul 2020
    Primary Completion
    Aug 2024
    Completion
    Aug 2024
    NCT04502446
  • Phase 1
    Completed

    An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D

    VCTX210A unit

    Diabetes Mellitus, Diabetes Mellitus, Type 1 +5

    Enrollment
    7
    Start
    Jan 2022
    Primary Completion
    Jan 2023
    Completion
    Jan 2023
    NCT05210530
  • Phase 1
    Terminated

    An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

    VCTX211

    Diabetes Mellitus, Diabetes Mellitus, Type 1 +5

    Enrollment
    5
    Start
    Jan 2023
    Primary Completion
    Aug 2025
    Completion
    Aug 2025
    NCT05565248
  • Phase 1
    Recruiting

    A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

    CTX112

    SLE (Systemic Lupus), Lupus Erythematosus, Systemic +5

    Enrollment
    80
    Start
    Mar 2025
    Primary Completion
    Dec 2031est.
    Completion
    Dec 2031est.
    NCT06925542
  • Phase 1
    Recruiting

    A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

    CTX310

    Cardiovascular, Metabolic Disease +8

    Enrollment
    90
    Start
    Jun 2024
    Primary Completion
    Jun 2027est.
    Completion
    Jun 2028est.
    NCT07491172
  • Observational
    Enrolling by invitation

    A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

    Non Interventional

    Hematologic Malignancy, Solid Malignancy

    Enrollment
    70
    Start
    Nov 2023
    Primary Completion
    Aug 2038est.
    Completion
    Aug 2038est.
    NCT06208878
Search ClinicalTrials.gov for “CRISPR Therapeutics”